Clinical Trial Update: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting completion of helminth-induced immunomodulation therapy (HINT) in Relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Helminth-induced Immunomodulation Therapy (HINT)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 1 | Status: COMPLETED